Iron dextran
As of the edition of 20 October 2026, Iron dextran is a drug: marketed, first approved in 1934 (CH).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Unknown
- Brand name
- Infed
- First approved
- 31 August 1934 (CH)
- Approvals on record
- 19 in 2 regions
- Holder of the most recent approval
- Baxter Healthcare; 9 holders in all
- Registered trials
- 8, 1 stopped early
- Disease areas
- Blood and lymph; Nutrition and metabolism; Cancer; Pregnancy and women's health; Urinary and reproductive; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 4 | 3 | 0 | 1 |
| Phase 3 | 1 | 1 | 0 | 0 |
| Phase 4 | 3 | 2 | 0 | 0 |
| All trials | 8 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| CSL Behring | Applicant | 1949 to now |
| Bayer | Later holder | 1984 to now |
| B. Braun Medical | Later holder | 1988 to now |
| New River Pharmaceuticals | Acquired holder | 2003 to now |
| Sanofi | Acquired holder | 2006 to now |
| AbbVie | Acquired holder | 2016 to now |
| Baxter Healthcare | Later holder | 2018 to now |
| American Regent | Acquired holder | 2020 to now |
| Fisons | Applicant |